We are live on
!
Find out more
CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
1-Year Est. Return
37.91%
This Fund
S&P 500
This Quarter
Est. Return
+2.79%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$125M
AUM Growth
-$8.83M
(-6.6%)
Cap. Flow
-$9.14M
Cap. Flow
% of AUM
-7.28%
Top 10 Holdings %
Top 10 Hldgs %
68.49%
Holding
30
New
7
Increased
6
Reduced
7
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$10.7M |
| 2 |
Gilead Sciences
GILD
|
+$9.26M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$9.24M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$5.98M |
| 5 |
Biogen
BIIB
|
+$4.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$10.3M |
| 2 |
HOLX
Hologic
HOLX
|
+$9.41M |
| 3 |
Puma Biotechnology
PBYI
|
+$6.5M |
| 4 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$6.08M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$5.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.21% |
| 2 | Consumer Discretionary | 2.79% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Intuitive Surgical
ISRG
$119B
| $9.74M | 7.76% |
70,764
+4,764
| +7% | +$665K |
|
2
Illumina
ILMN
$29.8B
| $9.33M | 7.44% |
40,583
-7,939
| -16% | -$1.82M |
|
|
3
Cigna
CI
$75.7B
| $9.23M | 7.35% |
+55,000
| New | +$10.7M |
|
|
4
Biogen
BIIB
$29.6B
| $9.12M | 7.27% |
33,296
+14,975
| +82% | +$4.65M |
|
|
5
Thermo Fisher Scientific
TMO
$213B
| $9.08M | 7.24% |
+44,000
| New | +$9.24M |
|
|
6
Gilead Sciences
GILD
$162B
| $8.78M | 7% |
+116,506
| New | +$9.26M |
|
7
Vertex Pharmaceuticals
VRTX
$120B
| $8.52M | 6.79% |
52,244
-10,047
| -16% | -$1.64M |
|
8
Stryker
SYK
$122B
| $8.37M | 6.67% |
52,009
+12,009
| +30% | +$1.94M |
|
9
Molina Healthcare
MOH
$10.5B
| $7.58M | 6.04% |
93,382
+46,382
| +99% | +$3.73M |
|
10
DaVita
DVA
$15B
| $6.21M | 4.95% |
94,126
-46,674
| -33% | -$3.43M |
|
|
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
| $5.65M | 4.5% |
375,370
-82,247
| -18% | -$1.25M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.57M | 4.44% |
+50,000
| New | +$5.98M |
|
13
Zoetis
ZTS
$31.3B
| $4.65M | 3.71% |
55,691
-1,027
| -2% | -$80.9K |
|
|
NUVA
14
DELISTED
NuVasive, Inc.
NUVA
| $4.57M | 3.64% |
87,569
+18,289
| +26% | +$927K |
|
15
Edwards Lifesciences
EW
$48.3B
| $4.21M | 3.35% |
90,474
-83,556
| -48% | -$3.63M |
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.75M | 2.99% |
71,092
+34,548
| +95% | +$2.02M |
|
17
Service Corp International
SCI
$10.9B
| $3.5M | 2.79% |
92,796
-1,698
| -2% | -$65.2K |
|
18
Heron Therapeutics
HRTX
$86.9M
| $2.98M | 2.38% |
+108,000
| New | +$2.45M |
|
|
CELG
19
DELISTED
Celgene Corp
CELG
| $2.51M | 2% |
+28,100
| New | +$2.7M |
|
|
ARRY
20
DELISTED
Array Biopharma Inc
ARRY
| $2.15M | 1.71% |
+131,418
| New | +$2.11M |
|
|
HOLX
21
DELISTED
Hologic
HOLX
| – | – |
-220,240
| Closed | -$9.41M |
|
|
22
CALL
Puma Biotechnology
PBYI
$408M
| – | – |
-37,000
| Closed | -$3.66M |
|
|
23
Puma Biotechnology
PBYI
$408M
| – | – |
-65,742
| Closed | -$6.5M |
|
|
AERI
24
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-78,132
| Closed | -$4.67M |
|
|
ADMS
25
DELISTED
Adamas Pharmaceuticals
ADMS
| – | – |
-77,517
| Closed | -$2.63M |
|
Similar funds
AAM
IR
YEPV
LC
MA
IFC
PVMCV
ARTA
Copernicus Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Copernicus Capital Management held 30 positions worth $125M, down 6.6% from $134M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Copernicus Capital Management withdrew a net $9.14M in Q1 2018, closing 10 positions and reducing 7 holdings. Its most notable exit was Aetna Inc, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 79% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Copernicus Capital Management opened a new position in Cigna worth $9.23M.
- Copernicus Capital Management's largest Q1 2018 buy was Cigna: 55,000 shares worth $9.23M.
- Copernicus Capital Management added most to Biogen in Q1 2018, an estimated $4.65M increase.
- Copernicus Capital Management's biggest Q1 2018 reduction was Edwards Lifesciences, cutting an estimated $3.63M.
- Copernicus Capital Management fully exited Aetna Inc in Q1 2018, selling an estimated $10.3M.
- Copernicus Capital Management's ten largest holdings make up 68% of its $125M portfolio in Q1 2018.
- Copernicus Capital Management opened 7 new positions and closed 10 in Q1 2018.
- Copernicus Capital Management's portfolio value fell 6.6% quarter-over-quarter to $125M.
Based on Copernicus Capital Management's 13F filing for Q1 2018, filed 1 May 2018.